MedTrace Logo

Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors

NCT00111241 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2018-12-14

Study results available
· View outcomes & findings →

Summary

Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body. Women on aromatase inhibitors appear to experience joint pains and arthralgia. The aim of this study is to determine whether the joint pains experienced by some women on aromatase inhibitors is associated with more defects in their cartilage, compared to women not receiving this therapy. Using the magnetic resonance imaging (MRI) technique, the knee joint will be examined to assess changes in cartilage volume over time.

Conditions

Interventions

DRUG

aromatase inhibitors (letrozole, anastrozole)

Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study

Sponsors & Collaborators

Principal Investigators

  • Susan Davis, MBBS PhD · Director Women's Health Program

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2011-05-31
Completion
2011-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00111241 on ClinicalTrials.gov